Información de la revista
Vol. 24. Núm. 7.
Páginas 352-356 (enero 2001)
Vol. 24. Núm. 7.
Páginas 352-356 (enero 2001)
Acceso a texto completo
Nuevas perspectivas en el tratamiento de la hepatitis crónica por virus C
Visitas
3469
M. Buti
Autor para correspondencia
mbuti@hg.vhebron.es
Correspondencia: Dra. M. Buti. Servicio de Hepatología. Hospital General Universitario Vall d'Hebron. P.o Valle Hebrón, 117. 08035 Barcelona
Correspondencia: Dra. M. Buti. Servicio de Hepatología. Hospital General Universitario Vall d'Hebron. P.o Valle Hebrón, 117. 08035 Barcelona
Servicio de Hepatología. Hospital General Universitario Vall d'Hebron. Barcelona. Universidad Autónoma. Barcelona
Este artículo ha recibido
Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
Anonymous. Global surveillance and control of hepatitis C.
Report of a WHO Consultation.
Viral Hepatitis, 6 (1999), pp. 35-47
[2.]
Anonymous. EASL International Consensus Conference on Hepatitis C.
Hepatol, 30 (1999), pp. 956-961
[3.]
Anonymous. National institutes of health consensus development conference panel statement. Management of hepatitis C.
Hepatology, 26 (1997), pp. 28-108
[4.]
J.G. McHutchison, S.C. Gordon, E.R. Schiff, M.L. Shiffman, W.M. Lee, V.K. Rustgi, et al.
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C.
N Engl J Med, 339 (1998), pp. 1485-1492
[5.]
T. Poynard, P. Marcellin, S.S. Lee, C. Niederau, G.S. Minuk, G. Ideo, et al.
Randomised trial of interferon a2b plus ribavirin for 48 weeks or 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus.
Lancet, 352 (1998), pp. 1426-1432
[6.]
O. Reichard, G. Norkrans, A. Fryden, J.H. Braconier, A. Sonnerborg, O. Weiland.
Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group.
Lancet, 351 (1998), pp. 1660-1664
[7.]
T. Poynard, J. McHutchison, Z. Goodman, M-H Ling, J. Albrecht.
Is an «a la carte» combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?.
Hepatology, 31 (2000), pp. 211-218
[8.]
D.T.Y. Lau, D.E. Kleiner, M.G. Ghany, Y. Park, P. Scmid, J.H. Hoofnagle.
10-year follow-up after interferon-α therapy for chronic hepatitis C.
Hepatology, 28 (1998), pp. 1121-1127
[9.]
P. Marcellin, N. Boyer, A. Gervais, M. Martinot, M. Pouteau, C. Castelnau, et al.
Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.
Ann Intern Med, 127 (1997), pp. 875-881
[10.]
O. Reichard, H. Glaumann, A. Fryden, G. Norkrans, R. Wejstal, O. Weiland.
Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon.
J Hepatol, 30 (1999), pp. 783-787
[11.]
P.F. Renault, J.H. Hoofnagle.
Side effects of alpha interferon.
Semin liver Dis, 9 (1989), pp. 273-277
[12.]
P. Glue, R. Rouzier-Panis, C. Raffanel, R. Sabo, S.K. Gupta, M. Salfi, et al.
A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C.
Hepatology, 32 (2000), pp. 647-653
[13.]
Taplaz, M, Cortes J, O'Brien S, Keating M, Files F, Rose E et al. Phase I study of polyethylene gycol (PEG) interferon alpha-2b (Introm A) in CML [resumen]. Blood; 92 (Supl): 251
[14.]
P. Glue, J.W.S. Fang, R. Sabo, R. Rouzier-Panis, C. Raffanel, R. Sabo, et al.
PEG-Interferon alfa-2b: pharmacokinetics, pharmakodynamics, safety and preliminary efficacy data.
Hepatology, 30 (1999), pp. 189
[15.]
S. Zeuzem, V. Feinman, J. Rasenck, J. Heatchote, M-YL Lai, E. Gane, et al.
Peginterferon alfa-2a in patients chronic hepatitis C.
N Engl J Med, 343 (2000), pp. 1666-1672
[16.]
C. Trepo, K. Lindsay, C. Niederau, M. Schiffman, S. Gordon, J. Hoefs, et al.
Pegylated interferon alfa-2b (PEG-INTRON) monotherapy is superior to interferon alfa-2b (INTRON A) for the treatment of chronic hepatitis C [resumen].
J Hepatol, 32 (2000), pp. 29
[17.]
E.J. Heatchote, M.L. Shiffman, W. Graham, E. Cooksley, G. Dusheiko, S.S. Lee, et al.
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.
N Engl J Med, 343 (2000), pp. 1673-1680
[18.]
Y. Imai, S. Kawata, S. Tamura, I. Yabuuchi, S. Noda, M. Inada, et al.
Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C.
Ann Intern Med, 129 (1998), pp. 94-99
[19.]
S. Nishiguchi, T. Kuroki, S. Nakatani, H. Morimoto, T. Takeda, S. Nakajima, et al.
Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.
Lancet, 346 (1995), pp. 1051-1055
[20.]
D.C. Valla, M. Chevallier, P. Marcellin, J.L. Payen, C. Trepo, M. Fonck, et al.
Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment.
Hepatology, 29 (1999), pp. 1870-1875
[21.]
S. Nishiguchi, S. Shiomi, S. Nakatani, T. Takeda, K. Fukuda, A. Tamori, et al.
Prevention of hepatocelullar carcinoma in patients with chronic active hepatitis C and cirrhosis.
Lancet, 357 (2001), pp. 196-197
[22.]
V. Baffis, I. Shrier, A.H. Sherker, A. Szilagyi.
Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection.
Ann Intern Med, 131 (1999), pp. 696-701
[23.]
D. Murphy, K.M. Detjen, M. Welzel, B. Wiedenmann, S. Rosewick.
Interferon alfa delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases.
Hepatology, 33 (2001), pp. 346-356
[24.]
M. Manns, J.C. McHutchison, S. Gorgon, V.K. Rustgi, M. Shiffman, R. Reindollar, et al.
Peginterferon alfa 2b plus ribavirin compared to interferon alfa2b plus ribavirin for the treatment of chronic hepatitis C: results of randomised trial.
The Lancet, (2001),
[25.]
N.P. Lam, A.U. Neumann, D.R. Gretch, T.E. Wiley, A.S. Perelson, T.J. Layden.
Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa.
Hepatology, 26 (1997), pp. 226-231
[26.]
S. Zeuzem, J.H. Lee, A. Franke, B. Ruster, O. Prummer, et al.
Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa.
Hepatology, 27 (1998), pp. 1149-1156
[27.]
F.C. Bekkering, J.T. Brouwer, G. Leroux-Roels, H. Van Vlierberghe, A. Elewaut, S.W. Schalm.
Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy.
J Hepatol, 28 (1998), pp. 960-964
[28.]
S. Zeuzem, J.M. Schmidt, J.H. Lee, M. Von Wagner, G. Teuber, W.K. Roth.
Hepatitis C dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover.
Hepatology, 28 (1998), pp. 245-252
[29.]
S. Zeuzem.
Clinical implications of hepatitis C viral kinetics.
J Hepatol, 31 (1999), pp. 61-64
[30.]
T.J. Layden.
Principles of interferon induction therapy.
Am J Med, 27 (1999), pp. S712-S773
[31.]
F.C. Bekkering, C. Stalgis, J.G. McHutchison, J.T. Brouwer, A.S. Perelson.
Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model.
Hepatology, 33 (2001), pp. 419-423
[32.]
G.L. Davis, R. Esteban-Mur, V. Rustgi, J. Hoefs, S.C. Gordon, C. Trepo, et al.
Interferon alfa2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C.
N Engl J Med, 339 (1998), pp. 1493-1499
[33.]
V. Di Marco, P. Almasio, A. Vaccaro, D. Ferraro, P. Parisi, M.G. Cataldo, et al.
Combined treatment of relapse of chronic hepatitis C with high-dose α2b interferon plus ribavirin for 6 or 12 months.
J Hepatol, 33 (2000), pp. 456-462
[34.]
S. Brillanti, J. Garson, M. Foli, K. Whitby, R. Deaville, C. Masci, et al.
A pilot study of combination therapy with ribavirin plus interferon for interferon -resistant chronic hepatitis C.
Gastroenterology, 107 (1994), pp. 812-817
[35.]
R. Schvarcz, Z.B. Yun, A. Sonnerborg, O. Weiland.
Combination treatment with interferon -2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone.
J Med Virol, 46 (1995), pp. 43-47
[36.]
J. Brouwer, F. Nevens, P. Michielsen.
What options are left when hepatitis C does not respond to interferon? Placebo-controlled Benelux multicentre retreatment trial on ribavirin monotherapy versus combination with interferon.
J Hepatol, 21 (1994), pp. 17A
[37.]
S. Pol, v.s. Ribavirin-interferon.
Interferon (alfa 2b-IFN) alone in non-responders to -2b IFN in chronic hepatitis C.
Hepatology, 24 (1996), pp. A356
[38.]
M. Buti, G. Olive, C. Stalgis, R. Esteban, J. Guardia.
Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C.
Dig Dis Sci, 45 (2000), pp. 1-5
[39.]
A. Bellobuono, L. Mondazzi, S. Tempini, F. Chiodo, E. Magliano, L. Furiano, et al.
Early addition of ribavirin to interferon in chronic hepatitis C not responsive to interferon monotherapy.
J Hepatol, 33 (2000), pp. 463-468
[40.]
Z.M. Younossi, K.D. Mullen, W. Zakko, S. Hodnick, E. Brand, D.S. Barnes, et al.
A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy.
J Hepatol, 34 (2001), pp. 128-133
Copyright © 2001. Elsevier España, S.L.. Todos los derechos reservados